MicroRNA-21 predicts response to preoperative chemoradiotherapy in locally advanced rectal cancer

International Journal of Colorectal Disease

Volumn 30, Issue 7, 2015, Pages 899-906

  Caramés, Cristina ^a   Cristóbal, Ion ^b   Moreno, Víctor ^a   del Puerto, Laura ^b   Moreno, Irene ^a   Rodriguez, María ^b   Marín, Juan P ^a   Correa, Andrea V ^a   Hernández, Roberto ^a   Zenzola, Víctor ^a   Hernández, Tatiana ^a   León, Ana ^a   Martín, José I ^a   Sánchez Fayos, Paloma ^a   García Olmo, Damián ^a   Rojo, Federico ^a   Goel, Ajay ^c   Fernandez Aceñero, María J ^a   García Foncillas, Jesús ^a,b  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^b 28400 Madrid   (Spain)

^c BAYLOR RESEARCH INSTITUTE   (United States)

Author keywords

Chemoradiotherapy; miR 21; Prognosis; Rectal cancer

Indexed keywords

CAPECITABINE; FLUOROURACIL; FORMALDEHYDE; MICRORNA 21; PARAFFIN; MICRORNA; MIRN21 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; COHORT ANALYSIS; CORRELATION ANALYSIS; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; RECTUM BIOPSY; RECTUM CARCINOMA; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; RECTAL NEOPLASMS; STATISTICAL MODEL; TREATMENT OUTCOME;

BIOMARKERS, TUMOR; CHEMORADIOTHERAPY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LOGISTIC MODELS; MALE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; RECTAL NEOPLASMS; ROC CURVE; TREATMENT OUTCOME;

EID: 84931563176     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-015-2231-9     Document Type: Article

References (38)

1. Rodel C, Hofheinz R, Liersch T (2012) Rectal cancer: state of the art in 2012. Curr Opin Oncol 24:441–447
2. Brenner H, Kloor M, Pox CP (2014) Colorectal cancer. Lancet 383:1490–1502
3. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R, German Rectal Cancer Study G (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740
4. Mamon HJ (2012) Long-term follow-up of a paradigm-changing study: the paradigm still holds. J Clin Oncol 30:1901–1903
5. Chetty R, Gill P, Govender D, Bateman A, Chang HJ, Deshpande V, Driman D, Gomez M, Greywoode G, Jaynes E, Lee CS, Locketz M, Rowsell C, Rullier A, Serra S, Shepherd N, Szentgyorgyi E, Vajpeyi R, Wang LM, Bateman A (2012) International study group on rectal cancer regression grading: interobserver variability with commonly used regression grading systems. Hum Pathol 43:1917–1923
6. Chetty R, Gill P, Bateman AC, Driman DK, Govender D, Bateman AR, Chua YJ, Greywoode G, Hemmings C, Imat I, Jaynes E, Lee CS, Locketz M, Rowsell C, Rullier A, Serra S, Szentgyorgyi E, Vajpeyi R, Delaney D, Wang LM (2012) Pathological grading of regression: an International Study Group perspective. J Clin Pathol 65:865–866
7. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC, Trial ERG (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114–1123
8. Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620–4625
9. Smith FM, Reynolds JV, Miller N, Stephens RB, Kennedy MJ (2006) Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Oncol 32:55–64
10. Nagtegaal ID, Gosens MJ, Marijnen CA, Rutten HJ, van de Velde CJ, van Krieken JH (2007) Combinations of tumor and treatment parameters are more discriminative for prognosis than the present TNM system in rectal cancer. J Clin Oncol 25:1647–1650
11. Quirke P, Steele R, Monson J, Grieve R, Khanna S, Couture J, O'Callaghan C, Myint AS, Bessell E, Thompson LC, Parmar M, Stephens RJ, Sebag-Montefiore D, MCN-CCT Investigators and NCCS Group (2009) Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 373:821–828
12. Casado E, Garcia VM, Sanchez JJ, Blanco M, Maurel J, Feliu J, Fernandez-Martos C, de Castro J, Castelo B, Belda-Iniesta C, Sereno M, Sanchez-Llamas B, Burgos E, Garcia-Cabezas MA, Mancenido N, Miquel R, Garcia-Olmo D, Gonzalez-Baron M, Cejas P (2011) A combined strategy of SAGE and quantitative PCR Provides a 13-gene signature that predicts preoperative chemoradiotherapy response and outcome in rectal cancer. Clin Cancer Res 17:4145–4154
13. Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M (2012) microRNAs in cancer management. Lancet Oncol 13:e249–e258
14. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H (2008) MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27:2128–2136
15. Yamamichi N, Shimomura R, Inada K, Sakurai K, Haraguchi T, Ozaki Y, Fujita S, Mizutani T, Furukawa C, Fujishiro M, Ichinose M, Shiogama K, Tsutsumi Y, Omata M, Iba H (2009) Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development. Clin Cancer Res 15:4009–4016
16. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM, Harris CC (2008) MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299:425–436
17. Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A (2013) Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst 105:849–859
18. Valeri N, Gasparini P, Braconi C, Paone A, Lovat F, Fabbri M, Sumani KM, Alder H, Amadori D, Patel T, Nuovo GL, Fishel R, Croce CM (2010) MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A 107:21098–21103
19. Deng J, Lei W, Fu JC, Zhang L, Li JH, Xiong JP (2014) Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro. Biochem Biophys Res Commun 443:789–795
20. Oue N, Anami K, Schetter AJ, Moehler M, Okayama H, Khan MA, Bowman ED, Mueller A, Schad A, Shimomura M, Hinoi T, Aoyagi K, Sasaki H, Okajima M, Ohdan H, Galle PR, Yasui W, Harris CC (2014) High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer. Int J Cancer 134:1926–1934
21. Altman DG, McShane LM, Sauerbrei W, Taube SE (2012) Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 9, e1001216
22. Greenson JK, Bonner JD, Ben-Yzhak O, Cohen HI, Miselevich I, Resnick MB, Trougouboff P, Tomsho LD, Kim E, Low M, Almog R, Rennert G, Gruber SB (2003) Phenotype of microsatellite unstable colorectal carcinomas: Well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am J Surg Pathol 27:563–570
23. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3:1101–1108
24. Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, Montagna C, Fuzesi L, Langer C, Becker H, Liersch T, Ried T (2005) Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 23:1826–1838
25. Kim IJ, Lim SB, Kang HC, Chang HJ, Ahn SA, Park HW, Jang SG, Park JH, Kim DY, Jung KH, Choi HS, Jeong SY, Sohn DK, Kim DW, Park JG (2007) Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer. Dis Colon Rectum 50:1342–1353
26. Rimkus C, Friederichs J, Boulesteix AL, Theisen J, Mages J, Becker K, Nekarda H, Rosenberg R, Janssen KP, Siewert JR (2008) Microarray-based prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer. Clin Gastroenterol Hepatol 6:53–61
27. Folkvord S, Flatmark K, Dueland S, de Wijn R, Groholt KK, Hole KH, Nesland JM, Ruijtenbeek R, Boender PJ, Johansen M, Giercksky KE, Ree AH (2010) Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling. Int J Radiat Oncol Biol Phys 78:555–562
28. Kheirelseid EA, Miller N, Chang KH, Curran C, Hennessey E, Sheehan M, Newell J, Lemetre C, Balls G, Kerin MJ (2013) miRNA expressions in rectal cancer as predictors of response to neoadjuvant chemoradiation therapy. Int J Colorectal Dis 28:247–260
29. Della Vittoria Scarpati G, Falcetta F, Carlomagno C, Ubezio P, Marchini S, De Stefano A, Singh VK, D'Incalci M, De Placido S, Pepe S (2012) A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 83:1113–1119
30. Svoboda M, Sana J, Fabian P, Kocakova I, Gombosova J, Nekvindova J, Radova L, Vyzula R, Slaby O (2012) MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat Oncol 7:195
31. Drebber U, Lay M, Wedemeyer I, Vallbohmer D, Bollschweiler E, Brabender J, Monig SP, Holscher AH, Dienes HP, Odenthal M (2011) Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy. Int J Oncol 39:409–415
32. Riordan AM, Thomas MK, Ronnekleiv-Kelly S, Warner T, Geiger PG, Kennedy GD (2012) Utility of micro-ribonucleic acid profile for predicting recurrence of rectal cancer. J Surg Res 177:87–92
33. Lopes-Ramos C, Habr-Gama A, Quevedo B, Felício N, Bettoni F, Koyama F, Asprino P, Galante P, Gama-Rodrigues J, Camargo A, Perez R, Parmigiani R (2014) Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients. BMC Med Genomics 7:68
34. Monzo M, Martínez-Rodenas F, Moreno I, Navarro A, Santasusagna S, Macias I, Muñoz C, Tejero R, Hernández R (2015) Differential MIR-21 Expression in Plasma From Mesenteric Versus Peripheral Veins: An Observational Study of Disease-free Survival in Surgically Resected Colon Cancer Patients. Medicine (Baltimore) 94, e145
35. Shan L, Ji Q, Cheng G, Xia J, Liu D, Wu C, Zhu B, Ding Y (2015) Diagnostic value of circulating miR-21 for colorectal cancer: A meta-analysis. Cancer Biomark 15:47–56
36. Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23:8688–8869
37. Suarez J, Vera R, Balen E, Gomez M, Arias F, Lera JM, Herrera J, Zazpe C (2008) Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer. Colorectal Dis 10:563–568
38. Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C, Feig BW, Das P, Krishnan S, Crane CH, Hu CY, Chang GJ (2012) Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol 30:1770–1776